U.S. markets closed

Zai Lab Limited (ZLAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
147.52+0.13 (+0.09%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Top

Double Top

Previous Close147.39
Open146.69
Bid147.52 x 800
Ask167.00 x 800
Day's Range144.37 - 150.88
52 Week Range43.06 - 193.54
Volume509,749
Avg. Volume369,181
Market Cap12.577B
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-3.39
Earnings DateAug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est155.52
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 15 Fastest Growing Biotech Companies in the US
    Insider Monkey

    15 Fastest Growing Biotech Companies in the US

    In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]

  • Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
    GlobeNewswire

    Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021

    Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report financial results for the full year ended December 31, 2020, and provide a corporate update before the opening of the U.S. equity markets on March 1, 2021. Conference Call and Webcast Information Zai Lab will host a live conference call and webcast on March 1, 2021 at 8:00 a.m. ET. Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link:http://apac.directeventreg.com/registration/event/3008148 Conference ID:3008148 All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call. A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide. For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global. For more information, please contact: ZAI LAB CONTACTS: Zai LabBilly Cho, CFO+86 137 6151 2501 billy.cho@zailaboratory.com Media: Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, on behalf of Zai Lab212-213-0006 ext. 315 / 364rimai@burnsmc.com / rflamm@burnsmc.com Investors: Pete Rahmer / Mike ZanoniEndurance Advisors, on behalf of Zai Lab415-515-9763 / 610-442-8570prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com Zai Lab Limited Source: Zai Lab Limited

  • GlobeNewswire

    Zai Lab Announces Upcoming Presentations in February Investor Conferences

    SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior management from Zai Lab will be presenting in the following upcoming virtual investor conferences in February. Details are as follows: Guggenheim Healthcare Talks 2021 Oncology DayFireside chat: Thursday, February 11, 2021 at 12:00 p.m. ET 2021 SVB Leerink Global Healthcare ConferencePresentation: Friday, February 26, 2021 at 8:00 a.m. ET A live webcast of the 2021 SVB Leerink Global Healthcare Conference presentation will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide. For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global. For more information, please contact: ZAI LAB CONTACTS: Zai LabBilly Cho, CFO+86 137 6151 2501 billy.cho@zailaboratory.com Media: Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, on behalf of Zai Lab212-213-0006 ext. 315 / 364rimai@burnsmc.com / rflamm@burnsmc.com Investors: Pete Rahmer / Mike ZanoniEndurance Advisors, on behalf of Zai Lab415-515-9763 / 610-442-8570prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com Zai Lab Limited Source: Zai Lab Limited